Soluble IL2 receptors help assess macrophages behavior. Ferritin also asses the same in Macrophage activation syndrome. ADA2 is the newer biomarker for hemophagocytic syndromes. #ACR25 @RheumNow Interferon gamma also a newer important target in MAS https://t.co/7sWwninBTM

• https://x.com/bella_mehta/status/1982903391761441134/photo/1

Simultaneous measurements if S100, Ferritin and IL-18 increase diagnostic utility of these biomarkers in Stills disease. @RheumNow #Acr25 https://t.co/3wmijNcpVY

• https://x.com/bella_mehta/status/1982902634936967446/photo/1

Low percentage of glycosylated Ferritin was more specific for Stills disease but not used frequently in clinical practice. @RheumNow #ACR25 https://t.co/wTK1eIcSKX

• https://x.com/bella_mehta/status/1982901974468345967/photo/1

#ACR25 Abstr#1532 “The more the merrier” or “Too many cooks..” Preliminary data of CTA313, dual CD19-BCMA CAR-T in 15 #SLE pts showed deep depletion & good response. Global study is planned. Will have to keep on eye on safety (G3 herpes zoster, pneumonia & neutropenia) @RheumNow https://t.co/0KQa9K6bYB

• https://x.com/Yuz6Yusof/status/1982900831436615909/photo/1

Biomarkers in Stills disease and MAS. #ACR25 @RheumNow IL 6 may not be helpful compared to CRP, and IL 1 beta is difficult to measure IL-18 seems to be the best one. https://t.co/u3oBTd4eaP

• https://x.com/bella_mehta/status/1982899918483374500/photo/1

#ACR25 Abstr#1608 10! 10! Across the board. 2-yr data from RCT + Open Label showed frequency of both airway and non-airway features of #EGPA improved with Benralizumab/Mepolizumab. Provides assurance to use more in real-world @RheumNow https://t.co/i78xXojGja

• https://x.com/Yuz6Yusof/status/1982897181272289562/photo/1

IL- 18 go together sometimes with glycolytic enzymes such as aldolase Also MAS may not be a switch on and off mechanism. Lastly MAS with Stills may have increased IL18 levels but not in other disease like SLE #ACR25 @RheumNow https://t.co/BW1fD7usBT

• https://x.com/bella_mehta/status/1982896532279177424/photo/1

What do we know about IL-18 Normal levels less than 500 Non specific 500 to 15000 Stills (quiet) 2000 to 10000 Mas/glares 20000 and more @RheumNow #ACR25 https://t.co/ZAltAD5Q8V

• https://x.com/bella_mehta/status/1982895598442557589/photo/1
• https://x.com/bella_mehta/status/1982895598442557589/photo/1

#ACR25 Abstr#1537 Beyond T-cell malignancy, we should be vigilant re: Local immune effector cell-associated toxicity syndrome (LICATS) with CAR-T. - Mostly afect skin & kidneys - Med time of onset 10 days; duration 11 days -Most LICATS were mild & without sequelae @RheumNow https://t.co/EnAWL936oh

• https://x.com/Yuz6Yusof/status/1982894724118917460/photo/1

AOSD And sJIA aren't the same disease!!!. Another take on this by Scott Canna..because the clinical syndrome might have somethings distinct!! #acr25 @RheumNow

Dr. Gensler gave a fantastic talk on SpA mimics ☝️Not all IBP is axSpA - interpret in the appropriate context + imaging WOF other mimics 🔸 Sacral insufficiency fractures 🔸 Infections 🔸DISH #ACR25 @RheumNow https://t.co/7TIqyp5rYe

• https://x.com/RHEUMarampa/status/1982894416579952700/photo/1
• https://x.com/RHEUMarampa/status/1982894416579952700/photo/1

In a Brazilian cohort (n=791), axSpA diagnosis delay dropped from 41.7 yrs (1960s) to 1.9 yrs (2020s). Female representation rose to 50%. Non-radiographic axSpA now 16.7%. MRI and updated criteria driving earlier, more equitable recognition. Abstract#1407 @RheumNow #ACR25 https://t.co/8hIpX0a1Sa

• https://x.com/synovialjoints/status/1982892555382518024/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow & its faculty.

Who talks to their neighbour? +SSA / Ro talk differently to nearby cells in #SjD #salivary #glands vs NEG Ro SjD Ro52 acts differently than Ro60 ?implications for Rx response? 🤷‍♀️ #ACR25 @RheumNow @ACRheum #Sjogren’s Abst#1684 #ACRBest! Elegant work from Sara McCoy https://t.co/UWUKAxi0UW

• https://x.com/Janetbirdope/status/1982889390893592682/photo/1
• https://x.com/Janetbirdope/status/1982889390893592682/photo/1
• https://x.com/Janetbirdope/status/1982889390893592682/photo/1

How many patients do you need to treat to prevent one RA conversion in at-risk individuals? APPIPRA and ALTO Interception studies, long term data Number Necessary to Treat to prevent 1 RA conversion across time: 1yr = 4 2yrs = 7 3, 4, 5 yrs = 9 6 yrs = 11 #ACR25 #ABSTRACT1678 https://t.co/GBzUJG8jVk

• https://x.com/AurelieRheumo/status/1982889500755013700/photo/1
• https://x.com/AurelieRheumo/status/1982889500755013700/photo/1